Condition
WHO Grade IV Glioma
Total Trials
4
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 2 (2)
Trial Status
Recruiting4
Clinical Trials (4)
Showing 4 of 4 trials
NCT05843253Phase 2Recruiting
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
NCT05839379Recruiting
Targeted Pediatric High-Grade Glioma Therapy
NCT06333899Early Phase 1Recruiting
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
NCT06161974Phase 2Recruiting
Study of Olutasidenib and Temozolomide in HGG
Showing all 4 trials